SCOTTWNY I think Dr. Bertolino answers your question whether 2 patients was sufficient in the 9/14/2017 PR Below.
Looks like 1 out of 10 would have been sufficient but 2 out of 2...
1st 2 hitters up knocked it out of the Park.
Something NO other Pharma has ever done without side effects.........JUST WOW!!!!!!!!!!!
September 14, 2017
Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial
Kevetrin
BEVERLY, Mass., Sep. 14, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that a new clinical site has been added in the Company’s Phase 2 clinical trial of Kevetrin for ovarian cancer. The site, a renowned academic medical center, is now actively enrolling patients.
In the interventional study, Kevetrin, Innovation Pharmaceutical’s novel p53-modulating drug candidate, is being evaluated in patients with platinum-resistant/refractory ovarian cancer. The primary outcomes for the study are incidence of treatment-emergent adverse events and evaluation of changes in cancer pathway biomarkers and molecular signatures, as measured in tissue/tumor samples pre-treatment and after three weeks of treatment.
“What we and potential partners are extremely interested in is learning via tumor biopsies if Kevetrin is reaching its target and modulating pathways within the tumor that can deliver a clinically meaningful benefit; this would be a significant development in the p53/oncology dynamic,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Innovation Pharmaceuticals. “If that is indeed the case in any number of patients, we will have compelling evidence to move forward expeditiously. A next step would be to complete development of an oral formulation of Kevetrin, which is the preferred delivery method of patients and facilitates the potential for multiple daily doses.”
Initial preliminary study results are anticipated in 4th quarter 2017.
